Posted by Michael Wonder on 23 Dec 2016
Novelion Therapeutics’ subsidiary files for European approval for metreleptin as a treatment for generalised lipodystrophy and a subset of patients with partial lipodystrophy
21 December 2016 - If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies.
Novelion Therapeutics today announced that its subsidiary has submitted a marketing authorisation application to the EMA seeking approval for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and in a subset of patients with partial lipodystrophy.
